Retinitis Pigmentosa (RP) Market Outlook

Thelansis’s “Retinitis Pigmentosa (RP) Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2026 To 2036” covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Retinitis Pigmentosa treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).

Retinitis Pigmentosa (RP) Overview

Retinitis pigmentosa (RP) is a group of inherited retinal dystrophies marked by progressive photoreceptor degeneration, driven by mutations across more than 80 genes (including RHO, USH2A, and RPGR). It exhibits a peripheral-to-central degeneration pattern where rod dysfunction typically precedes cone involvement. Patients present with early night blindness, progressive visual field constriction producing tunnel vision, and late-stage central blindness. Diagnosis integrates fundoscopic examination revealing characteristic bone-spicule deposits, electroretinography showing blunted responses, and genetic testing to confirm variants. The AAV-based gene therapy voretigene neparvovec represents a landmark precision standard specifically for biallelic RPE65 mutations. For the vast non-RPE65 population, vitamin A palmitate provides modest, heavily debated slowing. In 2026, the advanced therapeutic paradigm has shifted toward gene-agnostic restoration. This is led by the optogenetic gene therapy MCO-010 (sonpiretigen isteparvovec), which uses an AAV2 vector to express multi-characteristic opsins in retinal bipolar cells. In early 2026, its rolling BLA was completed following three-year REMAIN trial extension data showing durable, significant visual acuity gains. Low vision aids complete the modern management model.

Geography coverage:

G8 (United States, EU5 [France, Germany, Italy, Spain, U.K.], Japan, and China)

Insights driven by robust research, including:

• In-depth interviews with leading KOLs and payers
• Physician surveys
• RWE analysis for claims and EHR datasets
• Secondary research (e.g., peer-reviewed journal articles, third-party research databases)

Deliverables format and updates*:

• Detailed Report (PDF)
• Market Forecast Model (MS Excel-based automated dashboard)
• Epidemiology (MS Excel; interactive tool)
• Executive Insights (PowerPoint presentation)
• Others: regular updates, customizations, consultant support

*As per Thelansis’s policy, we ensure that we include all the recent updates before releasing the report content and market model.

Salient features of Market Forecast model:

• 10-year market forecast (2026–2036)
• Bottom-up patient-based market forecasts validated through the top-down sales methodology
• Covers clinically and commercially-relevant patient populations/ line of therapies
• Annualized drug-level sales and patient share projections
• Utilizes our proprietary Epilansis and Analog tool (e.g., drug uptake and erosion) datasets and conjoint analysis approach
• Detailed methodology/sources & assumptions
• Graphical and tabular outputs
• Users can customize the model based on requirements

Key business questions answered:

• How can drug development and lifecycle management strategies be optimized across G8 markets (US, EU5, Japan, and China)?
• How large is the patient population in terms of incidence, prevalence, segments, and those receiving drug treatments?
• What is the 10-year market outlook for sales and patient share?
• Which events will have the greatest impact on the market’s trajectory?
• What insights do interviewed experts provide on current and emerging treatments?
• Which pipeline products show the most promise, and what is their potential for launch and future positioning?
• What are the key unmet needs and KOL expectations for target profiles?
• What key regulatory and payer requirements must be met to secure drug approval and favorable market access?
• and more…

1. Key Findings and Analyst Commentary

• Key trends: market snapshots, SWOT analysis, commercial benefits and risk, etc..

2. Disease Context

• Disease definition, classification, etiology and pathophysiology, drug targets,etc.

3. Epidemiology

• Key takeaways
• Incidence / Prevalence
• Diagnosed and Drug-Treated populations
• Comorbidities
• Other relevant patient segments

4. Market Size and Forecast

• Key takeaways
• Market drivers and constraints
• Drug-class specific trends
• Country-specific trends

5. Competitive Landscape

• Current therapies
  • Key takeaways
  • Dx and Tx journey/algorithm
  • Key current therapies – profiles and KOL insights
• Emerging therapies
  • Key takeaways
  • Notable late-phase emerging therapies – profiles, launch expectations, KOL insights
  • Notable early-phase pipeline

6. Unmet Need and TPP Analysis

• Top unmet needs and future attainment by emerging therapies
• TPP analysis and KOL expectations

7. Regulatory and Reimbursement Environments (by country and payer insights)

8. Appendix (e.g., bibliography, methodology)